GlobeNewswire: Deciphera Pharmaceuticals, Inc. Contains the last 10 of 10 releaseshttp://www.globenewswire.com/External?Length=42024-03-29T01:35:29ZGlobeNewswirehttp://www.globenewswire.com/External?Length=4newsdesk@globenewswire.com (NewsDesk)https://www.globenewswire.com/news-release/2018/09/18/1572282/0/en/Deciphera-Pharmaceuticals-Appoints-Daniel-C-Martin-as-Chief-Commercial-Officer.html?f=22&fvtc=4&fvtv=38947Deciphera Pharmaceuticals Appoints Daniel C. Martin as Chief Commercial Officer2018-09-18T11:30:00Z<![CDATA[Oncology executive with more than 20 years of commercial strategy and operations experience in global and emerging biopharmaceutical companies Oncology executive with more than 20 years of commercial strategy and operations experience in global and emerging biopharmaceutical companies]]>https://www.globenewswire.com/news-release/2017/12/18/1263231/0/en/Deciphera-Pharmaceuticals-Inc-Added-to-Russell-2000-Index.html?f=22&fvtc=4&fvtv=38947Deciphera Pharmaceuticals, Inc. Added to Russell 2000® Index2017-12-18T12:00:00Z<![CDATA[WALTHAM, Mass., Dec. 18, 2017 (GLOBE NEWSWIRE) -- Deciphera Pharmaceuticals, Inc. (NASDAQ:DCPH), a clinical-stage biopharmaceutical company focused on addressing key mechanisms of tumor drug resistance, today announced that it has been added to the Russell 2000® Index, as part of Russell’s quarterly IPO additions, effective Friday, December 15, 2017, after market close.]]>https://www.globenewswire.com/news-release/2017/11/28/1206761/0/en/Deciphera-Pharmaceuticals-Inc-Announces-Orphan-Drug-Designation-from-the-EMA-for-DCC-2618-for-the-Treatment-of-Gastrointestinal-Stromal-Tumors.html?f=22&fvtc=4&fvtv=38947Deciphera Pharmaceuticals, Inc. Announces Orphan Drug Designation from the EMA for DCC-2618 for the Treatment of Gastrointestinal Stromal Tumors2017-11-28T12:00:00Z<![CDATA[WALTHAM, Mass., Nov. 28, 2017 (GLOBE NEWSWIRE) -- Deciphera Pharmaceuticals, Inc. (NASDAQ:DCPH) a clinical-stage biopharmaceutical company focused on addressing key mechanisms of tumor drug resistance, today announced that the European Medicines Agency (EMA) has granted orphan drug designation (ODD) to DCC-2618, the Company’s pan-KIT and PDGFRα inhibitor, for the treatment of gastrointestinal stromal tumors (GIST). According to the American Cancer Society, in 2015 approximately 5,000 patients were newly diagnosed with GIST in the United States and estimates for 5-year survival range from 48% to 90% depending upon the stage of the disease at diagnosis.]]>https://www.globenewswire.com/news-release/2017/11/21/1197953/0/en/Deciphera-Pharmaceuticals-Inc-to-Present-at-the-29th-Annual-Piper-Jaffray-Healthcare-Conference.html?f=22&fvtc=4&fvtv=38947Deciphera Pharmaceuticals, Inc. to Present at the 29th Annual Piper Jaffray Healthcare Conference2017-11-21T12:00:00Z<![CDATA[WALTHAM, Mass., Nov. 21, 2017 (GLOBE NEWSWIRE) -- Deciphera Pharmaceuticals, Inc. (NASDAQ:DCPH), a clinical-stage biopharmaceutical company focused on addressing key mechanisms of tumor drug resistance, today announced that Michael Taylor, Ph.D., President and Chief Executive Officer, will present at the 29th Annual Piper Jaffray Healthcare Confernce on Tuesday, November 28, 2017 at 1:30 p.m. ET at the Lotte New York Palace Hotel.]]>https://www.globenewswire.com/news-release/2017/11/20/1197352/0/en/Deciphera-Pharmaceuticals-Reports-Data-from-Ongoing-Phase-1-Clinical-Study-of-DCC-2618-at-the-22nd-Annual-Scientific-Meeting-and-Education-Day-of-the-Society-for-Neuro-Oncology.html?f=22&fvtc=4&fvtv=38947Deciphera Pharmaceuticals Reports Data from Ongoing Phase 1 Clinical Study of DCC-2618 at the 22nd Annual Scientific Meeting and Education Day of the Society for Neuro-Oncology2017-11-20T12:00:00Z<![CDATA[DCC-2618 shows encouraging clinical signal in a patient with glioblastoma multiforme (GBM) DCC-2618 shows encouraging clinical signal in a patient with glioblastoma multiforme (GBM)]]>https://www.globenewswire.com/news-release/2017/11/14/1185719/0/en/Deciphera-Pharmaceuticals-Inc-Announces-Third-Quarter-2017-Financial-Results-and-Corporate-Highlights.html?f=22&fvtc=4&fvtv=38947Deciphera Pharmaceuticals, Inc. Announces Third Quarter 2017 Financial Results and Corporate Highlights2017-11-14T12:00:00Z<![CDATA[-Presented Updated Clinical Data from Ongoing Phase 1 Trial of DCC-2618 at ESMO-]]>https://www.globenewswire.com/news-release/2017/11/10/1184539/0/en/Deciphera-Pharmaceuticals-Inc-Reports-Data-Analysis-from-the-Ongoing-Phase-1-Clinical-Trial-of-DCC-2618-at-the-Annual-Meeting-of-The-Connective-Tissue-Oncology-Society.html?f=22&fvtc=4&fvtv=38947Deciphera Pharmaceuticals, Inc. Reports Data Analysis from the Ongoing Phase 1 Clinical Trial of DCC-2618 at the Annual Meeting of The Connective Tissue Oncology Society2017-11-10T12:00:00Z<![CDATA[- Data Support the Selection of the Recommended Daily Dose of 150 mg -]]>https://www.globenewswire.com/news-release/2017/11/06/1175037/0/en/Deciphera-Pharmaceuticals-Inc-to-Report-Clinical-Data-with-DCC-2618-at-the-Upcoming-22nd-Annual-Scientific-Meeting-and-Education-Day-of-the-Society-for-Neuro-Oncology.html?f=22&fvtc=4&fvtv=38947Deciphera Pharmaceuticals, Inc. to Report Clinical Data with DCC-2618 at the Upcoming 22nd Annual Scientific Meeting and Education Day of the Society for Neuro-Oncology2017-11-06T13:17:35Z<![CDATA[WALTHAM, Mass., Nov. 06, 2017 (GLOBE NEWSWIRE) -- Deciphera Pharmaceuticals, Inc. (NASDAQ:DCPH) a clinical-stage biopharmaceutical company focused on addressing key mechanisms of tumor drug resistance, today announced that an abstract highlighting the company’s pan-KIT and PDGFRα inhibitor, DCC-2618 in patients with malignant gliomas, has been selected for a poster presentation at the 22nd Annual Scientific Meeting and Education Day of the Society for Neuro-Oncology (SNO) November 16-19, 2017 in San Francisco, CA.]]>https://www.globenewswire.com/news-release/2017/10/03/1140033/0/en/Deciphera-Pharmaceuticals-Announces-Closing-of-Initial-Public-Offering-and-Exercise-of-Option-to-Purchase-Additional-Shares.html?f=22&fvtc=4&fvtv=38947Deciphera Pharmaceuticals Announces Closing of Initial Public Offering and Exercise of Option to Purchase Additional Shares2017-10-03T11:30:00Z<![CDATA[WALTHAM, Mass., Oct. 03, 2017 (GLOBE NEWSWIRE) -- Deciphera Pharmaceuticals, Inc. (NASDAQ:DCPH), a clinical-stage biopharmaceutical company focused on addressing key mechanisms of tumor drug resistance, announced the closing of its initial public offering of 7,500,000 shares of its common stock at a public offering price of $17.00 per share. The gross proceeds from the initial public offering to Deciphera were approximately $127,500,000, before underwriting discounts and estimated offering expenses.]]>https://www.globenewswire.com/news-release/2017/09/28/1134118/0/en/Deciphera-Pharmaceuticals-Announces-Pricing-of-Initial-Public-Offering.html?f=22&fvtc=4&fvtv=38947Deciphera Pharmaceuticals Announces Pricing of Initial Public Offering2017-09-28T01:49:06Z<![CDATA[WALTHAM, Mass., Sept. 27, 2017 (GLOBE NEWSWIRE) -- Deciphera Pharmaceuticals, Inc. (NASDAQ:DCPH), a clinical-stage biopharmaceutical company focused on addressing key mechanisms of tumor drug resistance, today announced the pricing of its initial public offering of 7,500,000 shares of common stock at a public offering price of $17.00 per share for aggregate gross proceeds of $127,500,000. All of the shares of common stock are being offered by Deciphera. In addition, Deciphera granted the underwriters a 30-day option to purchase up to 1,125,000 additional shares of its common stock at the initial public offering price. The shares are scheduled to begin trading on the NASDAQ Global Select Market on September 28, 2017 under the ticker symbol “DCPH.” The offering is expected to close on October 2, 2017, subject to customary closing conditions.]]>